Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | PFKFB2 | O60825 | 3/20 | 0.38 |
| ▸ | PFKFB1 | P16118 | 3/20 | 0.38 |
| ▸ | PFKFB3 | Q16875 | 3/20 | 0.38 |
| ▸ | STAT3 | P40763 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.37 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.37 |
| ▸ | PGR | P06401 | 2/20 | 0.37 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10095398 | 0.88 | PFKFB3 (0.48) | SMN1; SMN2ARPFKFB2PFKFB1PFKFB3 | |
| SCHEMBL10193325 | 0.80 | L3MBTL1 (0.46) | ALDH1A1SMN1; SMN2MEN1TSHRKMT2A | |
| SCHEMBL981244 | 0.79 | PFKFB3 (0.43) | SMN1; SMN2TDP1MAPTPFKFB2PFKFB1 | |
| SCHEMBL981052 | 0.79 | MAPT (0.43) | ALDH1A1SMN1; SMN2MEN1TSHRKMT2A | |
| SCHEMBL10095347 | 0.79 | SMN1; SMN2 (0.47) | ALDH1A1SMN1; SMN2MEN1TSHRKMT2A | |
| SCHEMBL2884083 | 0.79 | ALDH1A1 (0.50) | ALDH1A1SMN1; SMN2MEN1TSHRKMT2A | |
| SCHEMBL16729372 | 0.78 | KIF11 (0.45) | KIF11ALDH1A1MAPTKDM4EKCNA3 | |
| SCHEMBL13153386 | 0.77 | KIF11 (0.44) | KIF11ALDH1A1MAPTKDM4EKCNA3 | |
| SCHEMBL980087 | 0.77 | MEN1 (0.47) | ALDH1A1SMN1; SMN2MEN1TSHRKMT2A | |
| SCHEMBL981609 | 0.75 | L3MBTL1 (0.45) | SMN1; SMN2TDP1MAPTPFKFB2PFKFB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8927576-B2 | HCV inhibitor and therapeutic agent combinations | PTC Therpeutics, Inc. (US) | 2015-01-06 | — | — | US | disclosed |
| US-8927576-B2 | HCV inhibitor and therapeutic agent combinations | PTC Therpeutics, Inc. (US) | 2015-01-06 | — | — | US | disclosed |
| US-20120027721-A1 | HCV Inhibitor and Therapeutic Agent Combinations | PTC THERAPEUTICS, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| US-20120027721-A1 | HCV Inhibitor and Therapeutic Agent Combinations | PTC THERAPEUTICS, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-20110268698-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110268698-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-8013006-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-20080096928-A9 | Indole compounds that modify translational control of Hepatitis C virus | PTC THERAPEUTICS, INC. | 2008-04-24 | — | — | US | disclosed |
| US-20080096928-A9 | Indole compounds that modify translational control of Hepatitis C virus | PTC THERAPEUTICS, INC. | 2008-04-24 | — | — | US | disclosed |
| US-20070299069-A1 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. | 2007-12-27 | — | — | US | disclosed |
| US-20070299069-A1 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. | 2007-12-27 | — | — | US | disclosed |
| US-20070299068-A1 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. | 2007-12-27 | — | — | US | disclosed |
| US-20070299068-A1 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. | 2007-12-27 | — | — | US | disclosed |
| US-20070299068-A1 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. | 2007-12-27 | — | — | US | disclosed |
| WO-2007084413-A2 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2007-07-26 | — | — | WO | disclosed |
| US-20060223863-A1 | Methods for treating Hepatitis C | KARP GARY M | 2006-10-05 | — | — | US | disclosed |
| US-20060189606-A1 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. | 2006-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096928-A9 | Indole compounds that modify translational control of Hepatitis C virus | EIF2AK2, INMT, IDO1 | KIF11 3708/4885ALDH1A1 1556/4885SMN1; SMN2 4841/4885 |
| US-20070299068-A1 | Methods for treating hepatitis C | HAVCR2, EIF2AK2, MAVS | KIF11 3685/4885ALDH1A1 1497/4885SMN1; SMN2 3609/4885 |
| US-20110268698-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, LIPC, HCCS | KIF11 3250/4885ALDH1A1 563/4885SMN1; SMN2 4206/4885 |
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | OAT, HAVCR2, HCCS | KIF11 3319/4885ALDH1A1 591/4885SMN1; SMN2 4525/4885 |
| US-20060189606-A1 | Methods for treating hepatitis C | HAVCR2, EIF2AK2, MAVS | KIF11 3685/4885ALDH1A1 1497/4885SMN1; SMN2 3609/4885 |
| US-20070299069-A1 | Methods for treating hepatitis C | HAVCR2, EIF2AK2, MAVS | KIF11 3685/4885ALDH1A1 1497/4885SMN1; SMN2 3609/4885 |
| US-20060223863-A1 | Methods for treating Hepatitis C | OAT, HAVCR2, HCCS | KIF11 3319/4885ALDH1A1 591/4885SMN1; SMN2 4525/4885 |
| US-20120027721-A1 | HCV Inhibitor and Therapeutic Agent Combinations | HAVCR2, SERPINB1, ENPEP | KIF11 3790/4885ALDH1A1 1067/4885SMN1; SMN2 4565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.